Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 9,500 Shares

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction on Monday, April 14th. The shares were sold at an average price of $69.81, for a total value of $663,195.00. Following the transaction, the vice president now owns 47,206 shares in the company, valued at $3,295,450.86. This trade represents a 16.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Edwards Lifesciences Trading Up 0.7 %

NYSE EW opened at $69.86 on Tuesday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The company’s 50-day moving average price is $71.28 and its 200-day moving average price is $70.76. The stock has a market cap of $41.07 billion, a PE ratio of 10.02, a PEG ratio of 4.82 and a beta of 1.15. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Truist Financial lowered their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research report on Friday. Barclays lifted their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Piper Sandler increased their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Finally, Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $78.55.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently made changes to their positions in the company. Norges Bank purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $610,895,000. Jennison Associates LLC purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $555,939,000. Vanguard Group Inc. raised its stake in Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after buying an additional 6,537,494 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Edwards Lifesciences by 475.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after buying an additional 3,506,886 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in Edwards Lifesciences during the 4th quarter valued at $213,844,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.